AtriCure ATRC Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Appendage management | $228.42M+3.7% | $220.18M+3.4% | $212.91M+4.7% | $203.29M+4.9% | $193.88M+4.4% | |
| Minimally invasive ablation | $37.65M-5.5% | $39.85M-7.4% | $43.01M-7.5% | $46.52M-6.8% | $49.9M-7.3% | |
| Open ablation | $191.18M+3.4% | $184.89M+4.1% | $177.56M+4.2% | $170.33M+4.2% | $163.44M+3.2% | |
| Pain management | $94.91M+5.9% | $89.62M+5.7% | $84.82M+6.3% | $79.81M+9.5% | $72.85M+8.0% | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| Europe | $63.37M+3.0% | $61.49M+3.9% | $59.18M+5.3% | $56.23M+6.6% | $52.72M+5.7% | |
| Other International | $7.35M+5.8% | $6.94M+3.7% | $6.69M+6.0% | $6.31M+9.7% | $5.75M+9.9% | |
| Total International | $101.73M+2.6% | $99.16M+3.6% | $95.69M+4.9% | $91.19M+5.6% | $86.36M+4.7% | |
| United States | $450.43M+3.5% | $435.37M+3.0% | $422.62M+3.4% | $408.76M+3.8% | $393.72M+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AtriCure break its business down?
- AtriCure (ATRC) reports revenue from contract with customer, excluding assessed tax by product across 4 parts — Appendage management, Minimally invasive ablation, Open ablation and Pain management. Each is extracted from the segment footnotes and tracked over time.
- Where does AtriCure's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AtriCure's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
